Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.
This report describes a patient with small-cell lung cancer who was infected with both Mycobacterium tuberculosis and non-tuberculous mycobacterium. He received irinotecan plus cisplatin, with and without rifampin. Rifampin slightly reduced the conversion of irinotecan to 7-ethyl-10-hydroxycamptothecin (SN-38), as determined by pharmacokinetic analysis. Rifampin may influence the metabolism and toxicity of irinotecan to some extent. However, there are possibilities to control M. tuberculosis and Mycobacterium avium complex infections in patients with small-cell lung cancer by using rifampin in combination with irinotecan plus cisplatin.
Yonemori
Kan
K
Department of Internal Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0051, Japan. kyonemor@ncc.go.jp
Takeda
Yuichiro
Y
Toyota
Emiko
E
Kobayashi
Nobuyuki
N
Kudo
Koichiro
K
D000904:Antibiotics, Antitubercular / Q000494:pharmacology / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000150:complications / Q000188:drug therapy*; D004347:Drug Interactions; D005965:Glucuronates / Q000493:pharmacokinetics; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000188:drug therapy; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy*
C114685:7-ethyl-10-hydroxycamptothecin beta-glucuronide; D000904:Antibiotics, Antitubercular; D000972:Antineoplastic Agents, Phytogenic; D005965:Glucuronates; D000077146:Irinotecan; D012293:Rifampin; D002166:Camptothecin